Strohal R, Prinz J C, Girolomoni G, Nast A
Department of Dermatology and Venerology, Federal Academic Teaching Hospital of Feldkirch, Feldkirch, Austria.
Department of Dermatology, University of Munich, Munich, Germany.
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2390-8. doi: 10.1111/jdv.13248. Epub 2015 Sep 14.
Each individual psoriasis patient has different expectations and goals for biological treatment, which may differ from those of the clinician. As such, a patient-centred approach to treatment goals remains an unmet need in psoriasis.
The aim of this study was to review available data on patients' and physicians' decision criteria and expectations of biological treatment for moderate-to-severe psoriasis with the aim of developing a core set of questions for clinicians to ask patients routinely to understand what is important to them and thus better align physicians' and patients' expectations of treatment with biologics and its outcomes.
A literature search was conducted to identify key themes and data gaps. Aspects of treatment relevant when choosing a biological agent for an individual patient were identified and compared to an existing validated instrument. A series of questions aimed at helping the physician to identify the particular aspects of treatment that are recognised as important to individual psoriasis patients was developed.
Key findings of the literature search were grouped under themes of adherence, decision-making, quality of life, patient/physician goals, communication, patient-reported outcomes, satisfaction and patient benefit index. Several aspects of treatment were identified as being relevant when choosing a biological agent for an individual patient. The questionnaire is devised in two parts. The first part asks questions about patients' experience of psoriasis and satisfaction with previous treatments. The second part aims to identify the treatment attributes patients consider to be important and may as such affect their preference for a particular biological treatment. The questionnaire results will allow the physician to understand the key factors that can be influenced by biological drug choice that are of importance to the patient. This information can be used be the physician in clinical decision making.
The questionnaire has been developed to provide a new tool to better understand and align patients' and physicians' preferences and goals for biological treatment of psoriasis.
每位银屑病患者对于生物治疗都有不同的期望和目标，这可能与临床医生的期望和目标有所不同。因此，以患者为中心的治疗目标方法在银屑病治疗中仍是一项未满足的需求。
本研究旨在回顾关于中重度银屑病患者及医生对生物治疗的决策标准和期望的现有数据，以便为临床医生制定一套核心问题，使其能够常规询问患者，从而了解对患者重要的因素，进而更好地使医生和患者对生物制剂治疗及其结果的期望保持一致。
进行文献检索以确定关键主题和数据缺口。确定了为个体患者选择生物制剂时与治疗相关的各个方面，并与现有的经过验证的工具进行比较。制定了一系列旨在帮助医生确定对个体银屑病患者而言被认为重要的治疗特定方面的问题。
文献检索的主要发现归为以下主题：依从性、决策制定、生活质量、患者/医生目标、沟通、患者报告的结果、满意度和患者获益指数。确定了为个体患者选择生物制剂时与治疗相关的几个方面。问卷分为两部分。第一部分询问患者的银屑病经历以及对先前治疗的满意度。第二部分旨在确定患者认为重要且可能影响其对特定生物治疗偏好的治疗属性。问卷结果将使医生了解生物药物选择可能影响的、对患者重要的关键因素。这些信息可供医生用于临床决策。
已开发出该问卷，以提供一种新工具，更好地理解和协调患者与医生对银屑病生物治疗的偏好和目标。
Zotero 插件